NCT06899334 Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in Healthy Participants
| NCT ID | NCT06899334 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | University Hospital, Basel, Switzerland |
| Condition | Healthy |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2025-04-01 |
| Primary Completion | 2026-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 24 participants in total. It began in 2025-04-01 with a primary completion date of 2026-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary objective of this study is to determine whether equivalent moderately high doses of LSD, psilocybin, and DMT produce qualitatively similar peak effects when the effect duration is standardized with ketanserin. A DMT infusion mimicking oral LSD and psilocybin administrations will be tested, as well as intravenously administered ketanserin.
Eligibility Criteria
Inclusion Criteria: 1. Good understanding of the German language 2. Understanding of procedures and risks associated with the study 3. Willing to adhere to the protocol and signing of the consent form 4. Willing to refrain from the consumption of illicit psychoactive substances during the study 5. Willing not to operate heavy machinery within 48 h after administration of a study substance 6. Willing to use effective birth control throughout study participation 7. Body mass index 17 - 34.9 kg/m2 Exclusion Criteria: 1. Relevant chronic or acute medical condition 2. Current or previous major psychiatric disorder (e.g. psychotic disorder) 3. Psychotic disorder or bipolar disorder in first-degree relatives 4. Hypertension (SBP\>140/90 mmHg) or hypotension (SBP\<85 mmHg) 5. Bradycardia (\< 45 bpm) 6. Prolonged QTc interval (males: \>450 ms, females: \>470 ms) 7. AV block II° (Mobitz type and Webckebach type) and III° 8. Hallucinogenic substance use (not including cannabis) more than 20 times or any time within the previous two months 9. Pregnancy or current breastfeeding 10. Participation in another clinical trial (currently or within the last 30 days) 11. Use of medication that may interfere with the effects of the study medication 12. Tobacco smoking (\>10 cigarettes/day) 13. Excessive consumption of alcoholic beverages (\>15 drinks/week)
Contact & Investigator
Matthias E Liechti, Prof. Dr. MD
PRINCIPAL INVESTIGATOR
University Hospital, Basel, Switzerland
Frequently Asked Questions
Who can join the NCT06899334 clinical trial?
This trial is open to participants of all sexes, aged 25 Years or older, studying Healthy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06899334 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06899334 currently recruiting?
Yes, NCT06899334 is actively recruiting participants. Contact the research team at matthias.liechti@usb.ch for enrollment information.
Where is the NCT06899334 trial being conducted?
This trial is being conducted at Basel, Switzerland.
Who is sponsoring the NCT06899334 clinical trial?
NCT06899334 is sponsored by University Hospital, Basel, Switzerland. The principal investigator is Matthias E Liechti, Prof. Dr. MD at University Hospital, Basel, Switzerland. The trial plans to enroll 24 participants.